昨日晚间，*ST长药发布公告称，公司及子公司河北羿珩科技有限责任公司于2026年2月24日新增7起诉 讼，涉案金额合计1788万元。截至该公告披露日，除已经披露的诉讼、仲裁事项外，公司及子公司连续 12个月内累计涉及的诉讼、仲裁事项涉案金额合计约5469.52万元，占最近一期经审计净资产绝对值的 12.64%。 与此同时，*ST长药提示，公司同日还收到深交所下发的《事先告知书》，公司触及相关规定的股票终 止上市情形，深交所拟决定终止公司股票上市交易。其股票自2026年1月26日开市起停牌。 随着《行政处罚决定书》的正式下达，投资者索赔依据已形成。上海沪紫律师事务所刘鹏律师表示，两 类投资者可向公司索赔： 一是在2019年3月30日至2024年4月29日期间买入*ST长药股票，并在2024年4月29日收盘时仍持有该股 票的投资者；二是在2022年4月28日至2025年11月7日（含当日）期间买入*ST长药股票，并在2025年11 月7日收盘时仍持有该股票的投资者。 符合上述任一条件的投资者，可报名参与索赔。最终索赔条件以 法院认定为准。 内容来源：大众证券报 1月23日晚间，*ST长药相继发布了包括公司股票停牌 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 FF301 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 致：香港交易及結算所有限公司 公司名稱: 美亞娛樂資訊集團有限公司 （於百慕達註冊成立之有限公司） 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00391 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 15,000,000,000 | HKD | | 0.02 | HKD | | 300,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | 0 | | 本月底結存 | ...

Core Viewpoint - *ST Changyao has been penalized for financial fraud, facing a fine of 10 million yuan and a proposed termination of its stock listing due to serious violations over three consecutive years [2][5][7]. Group 1: Financial Penalties and Violations - The company was fined 10 million yuan for financial fraud, as confirmed by the China Securities Regulatory Commission (CSRC) [2][5]. - The CSRC has indicated that it will transfer any criminal evidence related to the case to the public security authorities for further investigation [2]. - The company has been found to have inflated revenue and profit figures in its annual reports from 2021 to 2023, with inflated revenues of 215 million yuan, 284 million yuan, and 234 million yuan, representing 9.12%, 17.57%, and 19.51% of reported revenues respectively [5]. Group 2: Stock Listing Status - The Shenzhen Stock Exchange has issued a notice proposing to terminate the company's stock listing, with trading suspension set to begin on January 26, 2026 [6][7]. - The company has already triggered conditions for mandatory delisting due to significant legal violations [9]. - The stock has experienced a significant price increase, with a cumulative rise of 107.75% over four trading days leading up to January 23, 2026 [9].

Core Viewpoint - *ST Changyao has been penalized for financial fraud, facing a fine of 10 million yuan and a proposed termination of its stock listing due to serious violations over three consecutive years [1][2]. Group 1: Financial Fraud Details - The company was found to have inflated revenue by 215 million yuan, 284 million yuan, and 234 million yuan for the years 2021, 2022, and 2023 respectively, which accounted for 9.12%, 17.57%, and 19.51% of the reported revenue for those years [4]. - The inflated total profit for the same years was 56.4 million yuan, 63.4 million yuan, and 43.7 million yuan, representing 35.62%, 88.23%, and 6.42% of the reported profit [4]. - An additional profit inflation of 4.55 million yuan was noted for 2022 due to improper loss recognition related to a project, which constituted 6.34% of the reported profit for that year [5]. Group 2: Regulatory Actions - The China Securities Regulatory Commission (CSRC) issued an administrative penalty decision on January 23, confirming the company's violations and imposing a fine [2][5]. - The company is subject to potential criminal prosecution as the CSRC has indicated it will refer any criminal evidence to the public security authorities [1]. - According to the Shenzhen Stock Exchange rules, the company has triggered conditions for mandatory delisting due to significant legal violations [8]. Group 3: Market Reaction - *ST Changyao's stock experienced a significant increase, with a cumulative price increase of 41.44% over two trading days and 107.75% over four trading days leading up to January 23 [8]. - As of January 23, the stock closed at 0.92 yuan per share, with a total market capitalization of 322 million yuan [8].

Group 1 - *ST Changyao has been found to have committed violations related to financial reporting, including the acquisition of 52.75% of Hubei Changjiang Star Pharmaceutical Co., Ltd. in November 2020, which was subsequently consolidated into its financial statements [2] - From 2021 to 2023, subsidiaries of Changjiang Star fabricated inventory and sales documents, leading to inflated revenues of 215.32 million, 283.74 million, and 233.63 million yuan for the respective years, representing 9.12%, 17.57%, and 19.51% of reported revenues [3] - The inflated total profits for the same years were 56.40 million, 63.38 million, and 43.71 million yuan, accounting for 35.62%, 88.23%, and 6.42% of the reported total profits [3] Group 2 - The company has been warned that its financial reporting from 2021 to 2023 contains false records, which may lead to the termination of its stock listing under the revised rules of the Growth Enterprise Market [3] - As of January 23, *ST Changyao's stock has experienced a continuous rise, with a total increase of 109.09%, reaching a price of 0.92 yuan per share and a market capitalization of 322 million yuan [4] Group 3 - The current regulatory environment is increasingly focused on combating financial fraud, with multiple departments collaborating to strengthen oversight and enforcement against such practices [6] - A recent meeting highlighted a shift in regulatory strategy from reactive punishment to proactive prevention and comprehensive accountability across all parties involved, including major shareholders and intermediaries [6] - The establishment of a comprehensive prevention and punishment system aims to enhance the integrity of the capital market, ensuring that fraudulent activities are met with severe consequences and that investors have avenues for compensation [6]

公告突发。 *ST长药（300391）1月23日晚间公告称，公司当天收到中国证监会下发的《行政处罚决定书》。 经查明，*ST长药存在以下违法事实： 2020年11月，*ST长药通过支付现金方式收购湖北长江星医药股份有限公司（简称"长江星"）52.75%的 股权。同年12月，长江星纳入*ST长药财务报表合并范围。长江星原实际控制人罗某等对长江星2020年 至2022年净利润等指标进行了业绩承诺。上述收购完成后，罗某继续担任长江星董事长、总经理，全面 负责长江星的经营管理工作。 2021年至2023年，长江星子公司湖北长江源制药有限公司、湖北新峰制药有限公司制作虚假的入库单、 出库单等，在没有发生真实销售业务的情况下确认收入，导致*ST长药2021年至2023年年度报告分别虚 增营业收入21532.38万元、28373.66万元、23363.46万元，占当期对外披露营业收入的9.12%、17.57%、 19.51%；虚增利润总额5640.14 万元、6337.52万元、4370.50万元，占当期对外披露利润总额绝对值的 35.62%、88.23%、6.42%。同时，由于2022年对长江伟创中药城交易中心工程项目未 ...

Group 1 - The core issue is that *ST Changyao has been penalized by the China Securities Regulatory Commission (CSRC) for financial misconduct, including false reporting of revenues and profits from 2021 to 2023, leading to a fine of 10 million yuan [2] - The company inflated its operating income by 215 million yuan, 284 million yuan, and 234 million yuan for the years 2021, 2022, and 2023, respectively, which accounted for 9.12%, 17.57%, and 19.51% of the reported operating income for those years [2] - The inflated total profit amounted to 56.4 million yuan, 63.4 million yuan, and 43.7 million yuan for the same years, representing 35.62%, 88.23%, and 6.42% of the reported total profit [2] Group 2 - The Hubei Securities Regulatory Bureau stated that *ST Changyao's continuous financial fraud is severe and has significantly harmed investors' interests, disrupting the normal order of the capital market [2] - The CSRC demonstrated a strong stance against market irregularities by processing the case from initiation to penalty decision in just over two months, reflecting a "zero tolerance" policy [2] - On January 23, *ST Changyao announced it received a notice from the Shenzhen Stock Exchange regarding the potential termination of its stock listing, with trading suspension set to begin on January 26 [4] Group 3 - As of January 23, *ST Changyao's stock closed at 0.92 yuan per share, with a total market capitalization of 322 million yuan [7] - The stock experienced a speculative surge, with a cumulative price deviation of 41.44% and a total deviation of 107.75% over four consecutive trading days [5] - The Hubei Securities Regulatory Bureau warned that the recent price movements are typical speculative trading, ignoring the reality of the company's impending administrative penalties and potential delisting due to serious violations [7]

公告突发。 *ST长药（300391）1月23日晚间公告称，公司当天收到中国证监会下发的《行政处罚决定书》。 经查明，*ST长药存在以下违法事实： 2020年11月，*ST长药通过支付现金方式收购湖北长江星医药股份有限公司(简称"长江星")52.75%的股权。同年12月，长江星纳入 *ST长药财务报表合并范围。长江星原实际控制人罗某等对长江星2020年至2022年净利润等指标进行了业绩承诺。上述收购完成 后，罗某继续担任长江星董事长、总经理，全面负责长江星的经营管理工作。 2021年至2023年，长江星子公司湖北长江源制药有限公司、湖北新峰制药有限公司制作虚假的入库单、出库单等，在没有发生真 实销售业务的情况下确认收入，导致*ST长药2021年至2023年年度报告分别虚增营业收入21532.38万元、28373.66万元、23363.46 万元，占当期对外披露营业收入的9.12%、17.57%、19.51%；虚增利润总额5640.14万元、6337.52万元、4370.50万元，占当期对外 披露利润总额绝对值的35.62%、88.23%、6.42%。同时，由于2022年对长江伟创中药城交易中心工程项目未合理确 ...

1月23日晚，*ST长药（300391）发布公告，公司于1月23日收到深交所下发的《事先告知书》，拟决定 终止公司股票上市交易。公司股票自1月26日开市起停牌。 湖北证监局表示，*ST长药连续多年财务造假，性质恶劣，严重损害广大投资者利益，扰乱了资本市场 正常秩序。证监会在*ST长药财务造假案件查处过程中，从立案到下发行政处罚决定书仅用时两个多 月，充分彰显了监管机构对资本市场乱象"零容忍"的坚决态度以及保护投资者合法权益的坚定决心。 值得注意的是，今天A股出现了"小强大弱"的普涨行情，濒临退市的*ST长药、*ST立方等连续4天盘中触 及20%涨停。*ST长药今晚发布的股价异动公告显示，公司股票于1月22日、1月23日连续2个交易日内日 收盘价格涨幅偏离值累计41.44%，于1月20日至1月23日连续4个交易日内日收盘价格涨幅偏离值累计 107.75%。 湖北证监局表示，近期市场对"*ST"相关概念进行投机性炒作，*ST长药、*ST立方等面临重大违法退市 风险的股票连续涨停。当前的股价异动，无视上市公司面临行政处罚、将因重大违法强制退市的现实， 是典型的投机炒作，积聚了巨大的投资风险，广大投资者应坚守理性投资 ...

面临重大违法强制退市、交易类强制退市、财务类强制退市等三重退市风险的*ST长药（300391），迎 来了毫无意外的结局。 1月23日晚间，*ST长药发布公告称，公司当日收到证监会下发的《行政处罚决定书》。经证监会查 明，*ST长药2021年至2023年年度报告存在虚假记载。证监会决定对*ST长药责令改正，给予警告，并 处以1000万元罚款。同时，因*ST长药触及重大违法强制退市情形，公司股票将于2026年1月26日起停 牌，深圳证券交易所将依规启动退市程序。 退市风险重重，仍被炒至"四连板" 此前，*ST长药因涉嫌定期报告等财务数据虚假记载，被中国证监会立案调查，公司及相关人员于2025 年12月26日收到中国证监会下发的《行政处罚事先告知书》。公司2021年、2022年、2023年年度报告存 在虚假记载，可能触及重大违法强制退市情形，公司股票可能被实施重大违法强制退市。公司股票交易 于2025年12月29日起被叠加实施退市风险警示。 有接受采访的券商人士表示，*ST长药连续多年财务造假，性质恶劣，严重损害广大投资者利益，扰乱 了资本市场正常秩序。证监会在*ST长药财务造假案件查处过程中，从立案到下发行政处罚 ...